Complement fixing and lymphocytotoxic antibodies in serum of pregnant women at delivery. III. Clinical observations.
The investigation comprised 2,008 pregnancies. Sera fnd lymphocytotoxic antibodies (LCTAb). 14 women had only CFPAb, 44 had CFPAb and LCTAb, 224 had only LCTAb. In 3 of 481 cord blood serum samples LCTAb were demonstrated. No cases of neutropenia or thrombocytopenia was observed. No association was found between CFPAb or LCTAb and stillbirth, birth defects, degree of bilirubinaemia, diseases of the newborn, or placental weight. It was suggested that the applied lymphocytotoxicity test detects both in vivo cytolytic antibodies and enhancing antibodies, which may explain the results.
D000906:Antibodies / Q000032:analysis*; D001724:Birth Weight; D003168:Complement Fixation Tests; D005260:Female; D005313:Fetal Death; D006801:Humans; D006932:Hyperbilirubinemia; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases; D007743:Labor, Obstetric; D008233:Lymphotoxin-alpha; D009929:Organ Size; D010920:Placenta; D011247:Pregnancy
D000906:Antibodies; D008233:Lymphotoxin-alpha